Results 141 to 150 of about 60,395 (277)

Colorectal Precancerous Lesions: Molecular Mechanisms, Research Tools, and Natural Product‐Based Clinical Translation

MedComm – Oncology, Volume 5, Issue 2, June 2026.
This article systematically elucidates the molecular mechanisms of colorectal precancerous lesions, introduces cutting‐edge research tools like multi‐omics and organoids, and highlights the potential and prospects of natural products such as berberine, resveratrol, and curcumin in preventing and intervening in colorectal carcinogenesis by modulating ...
Shunji Liu, Chujuan Cui, Lingdong Kong, Qiang Xu, Haibo Cheng, Lisha Zhou, Yang Sun   +6 more
wiley   +1 more source

A Review of Natural and Synthetic Chalcones as Anticancer Agents Targeting Topoisomerase Enzymes

Molecules
Cancer remains one of the leading causes of morbidity and mortality worldwide, driving the search for innovative and selective therapeutic agents. Topoisomerases I and II are essential enzymes involved in key cellular processes such as DNA replication ...
François-Xavier Toublet, Aurélie Laurent, Christelle Pouget   +2 more
doaj   +1 more source

Molecular and cellular effects of the combined treatment with Camptothecin and Roscovitine in human lung and colon adenocarcinoma cells [PDF]

, 2008
De Mattia, Roberta
core   +1 more source

Pitfalls and missing links in current understanding of 4D genomes

Quantitative Biology, Volume 14, Issue 2, June 2026.
Abstract The spatial and temporal organization of the genome—collectively termed the 4D genome—is pivotal for regulating gene expression, maintaining genome stability, and guiding development. The convergence of chromosome conformation capture technologies, super‐resolution microscopy, and single‐cell epigenomics has transformed our understanding of ...
Michael Q. Zhang
wiley   +1 more source

Trastuzumab Deruxtecan for HER2‐Low Metastatic Breast Cancer: Practical Considerations for Medical Oncologists and Pathologists in Australia

Asia-Pacific Journal of Clinical Oncology, Volume 22, Issue 3, Page 381-391, June 2026.
ABSTRACT Trastuzumab deruxtecan (T‐DXd) is a third‐generation, HER2‐targeting antibody‐drug conjugate that has been shown to significantly prolong overall survival, compared with standard chemotherapy, when used to treat patients who have “HER2‐low” (HER2 immunohistochemistry [IHC] score 1+; or HER2 IHC 2+ plus in situ hybridization‐negative ...
Andrew Redfern, Elgene Lim, Sunil Lakhani, Nirmala Pathmanathan, Sudarsha Selva‐Nayagam, Nicole McCarthy, Belinda Yeo, Benjamin Dessauvagie, Gelareh Farshid   +8 more
wiley   +1 more source

Benzoxazines as new human topoisomerase I inhibitors and potential poisons. [PDF]

Daru, 2020
Foto E, Özen Ç, Zilifdar F, Tekiner-Gülbaş B, Yıldız İ, Akı-Yalçın E, Diril N, Yalçın İ.   +7 more
europepmc   +1 more source

Ferrocene‐Based Sensors for Green Analytical Applications in Environmental, Biomedical, Industrial, and Food Monitoring

ChemistryOpen, Volume 15, Issue 5, May 2026.
Ferrocene derivatives represent a transformative class of molecular sensors, combining exceptional electrochemical stability with tunable redox characteristics that enable precise detection across diverse analytical challenges in environmental, medical, and industrial applications.
Ala'a Al‐Akhras, Asma Ghazzy, Zainab Zakaraya, Ala'a S. Shraim, Obada A. Sibai, Laila Alsabbagh, Deeb Taher   +6 more
wiley   +1 more source

Topoisomerase-I inhibitors in gynaecologic tumours.

Annals of the Academy of Medicine, Singapore, 1999
Topoisomerase inhibitors have been studied using various dose schedules in the treatment of refractory or recurrent gynaecologic cancers. Response rates are between 13% and 20%. Main toxic effects are haematologic and gastrointestinal. The latter remains problematic. Radiotherapy, alkylate, platinum analogs and topoisomerase II inhibitors are currently
C F, Verschraegen, A P, Kudelka, J J, Kavanagh   +2 more
openaire   +1 more source

The relationship between the cannabinoids and cardiac remodelling: A comprehensive review of pivotal mechanisms and emerging evidence

British Journal of Pharmacology, Volume 183, Issue 9, Page 1747-1778, May 2026.
Cardiac remodelling and fibrosis after myocardial infarction or during chronic diseases, such as arterial and pulmonary hypertension or diabetes mellitus, continue to be the more important prognostic factors in determining survival, and so the search for effective anti‐fibrotic interventions is an important target for research and therapy in cardiology.
Anna Krzyżewska, Marta Baranowska‐Kuczko, Hanna Kozłowska   +2 more
wiley   +1 more source

Novel drugs approved by the EMA, the FDA and the MHRA in 2025: A year in review

British Journal of Pharmacology, Volume 183, Issue 9, Page 1779-1813, May 2026.
Abstract In the 2025 novel drug mini‐review, one can take a full measure of the ingenuity that underlies current drug design and development, despite the year's smaller harvest (46 novel drugs) compared to 2024 (53) and 2023 (70). 54% of the novel drugs are first‐in‐class (FIC).
Andreas Papapetropoulos, Stavros Topouzis, Steve P. H. Alexander, Miriam M. Cortese‐Krott, Zsuzsanna Helyes, Kirill Martemyanov, Claudio Mauro, Nithyanandan Nagercoil, Reynold A. Panettieri Jr, Hemal H. Patel, Rainer Schulz, Barbara Stefanska, Gary J. Stephens, Nathalie Vergnolle, Xin Wang, Stephen Ward, Péter Ferdinandy   +16 more
wiley   +1 more source